Listed by the USPTO as POLIAKOVA-GEORGAN, EKATERINA
Tech Center 1600 • Art Units: 1600 1632 1635 1637 1651 1674 1699
This examiner grants 64% of resolved cases
Ekaterina Poliakova-Georgan has 690 resolved cases in Tech Center 1600 and Art Unit 1600. Her profile records a 63.9% allowance rate and a median of 943 days to allowance. Interviews are associated with an 18.1% lift in the allowance rate. These figures provide a prosecution baseline for applicants handling biotechnology and pharmaceutical matters in the identified examination group.
The leading companies are Ionis Pharmaceuticals Inc., The Trustees of Columbia University in the City of New York, and Alnylam Pharmaceuticals Inc. The leading firms are Barron & Young PLLC, Lathrop GPM LLP, and MCCARTER & ENGLISH, LLP. Practitioners can use the profile to evaluate expected examination duration and whether interview practice should be integrated into claim and amendment planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18380871 | CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18251562 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 17919459 | COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18439648 | Inhibition of Tau Propagation | Non-Final OA | The Regents of the University of California |
| 18607846 | MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION | Non-Final OA | KING'S COLLEGE LONDON |
| 18007609 | NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF | Final Rejection | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 17928463 | TREM COMPOSITIONS AND METHODS RELATING THERETO | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18577797 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING AGE-RELATED CONDITIONS | Non-Final OA | The Hong Kong University of Science and Technology |
| 18570914 | SYSTEMS, METHODS, AND COMPONENTS FOR RNA-GUIDED EFFECTOR RECRUITMENT | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18154728 | TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18037708 | VECTORS, SYSTEMS AND METHODS FOR EUKARYOTIC GENE EDITING | Non-Final OA | Wake Forest University Health Sciences |
| 17938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | Final Rejection | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18292680 | METHOD FOR NARROWING EDITING WINDOW OF BASE EDITOR, BASE EDITOR, AND USE | Non-Final OA | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.9% of resolved applications examined by Ekaterina Poliakova-Georgan were allowed (690 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +18.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ekaterina Poliakova-Georgan took 943 days on average from filing to allowance.
Ekaterina Poliakova-Georgan examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
